Clinical evidence reveals substantial increases in caspase-1 and IL-1β activation correlating with NASH progression, where inflammasome triggering exacerbates lipid accumulation, inflammatory responses, and fibrotic transformation [10, 25, 36]. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatohepatitis.